ST1326 (teglicar) is a preclinical-stage CPT1 inhibitor with demonstrated antitumor effects, particularly when combined with Bcl-2 inhibitors (e.g., ABT199) in acute myeloid leukemia (AML) [139–142]. The gene discussed is CPT2; the disease is acute myeloid leukemia.